As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Oral Mucositis – Drug Pipeline Landscape, 2023 globally. Oral Mucositis – Drug Pipeline Landscape, 2023 report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
“Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key –https://www.globalinsightservices.com/request-sample/GIS31248
Oral Mucositis also called as stomatitis is an acute inflammation of the mucous membranes of mouth/oral cavity following the systemic cancer therapy and/or radiation therapy.
The most common cause of Oral Mucositis is cancer treatments. The frequent treatments of chemotherapy, radiation of the head, chest, or neck, bone marrow and stem cell transplants can cause mucositis.
Symptoms include dry mouth, shiny, swollen, or red gums, mouth pain, painful mouth sores, infection, blood in the mouth, pain or a mild burning sensation while eating, difficulty in swallowing or talking.
Doctors can generally make a diagnosis based on the timing of symptoms relative to therapy and the clinical appearance of mouth. There is no laboratory or radiographic testing that is needed to make the diagnosis. Because viral or fungal (yeast) infections can occur in mouth, especially if white blood cell count is low, a culture, or a scraping may be done to rule out an infection.
Free customization available –https://www.globalinsightservices.com/request-customization/GIS31248
The most common treatments for Oral Mucositis are medication and mouthwashes and oral care.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Oral Mucositis treatment such as SGX942, Avasopasem, EC-18 and others. Key players involved in the development of therapies to treat Oral Mucositis are Soligenix, Galera Therapeutics, Enzychem Lifesciences Corp, and others. One drug is under Pre-Registration, one drug is under Phase III and four drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA filed, preclinical and discovery stages of development.
In December 2022, Galera Therapeutics submitted New Drug Application (NDA) to the U.S. Food and Drug Administration for Avasopasem for severe oral mucositis.
Report Highlights
Global Insight Service’s, Oral Mucositis – Drug Pipeline Landscape, 2023 report provides an overview of the Oral Mucositis pipeline drugs. This report covers detailed insights on Oral Mucositis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Oral Mucositis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31248
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700
Website: https://www.globalinsightservices.com/